Please use this identifier to cite or link to this item: http://hdl.handle.net/10773/16466
Title: Compliance to radiation therapy of head and neck cancer patients and impact on treatment outcome
Author: Ferreira, B. C.
Sá-Couto, P.
Lopes, M. C.
Khouri, L.
Keywords: Clinical outcome
Head and neck cancer
IMRT
Radiation therapy
Treatment interruptions
Issue Date: Jul-2016
Publisher: Springer Verlag
Abstract: AIMS: The aims of the study were to evaluate head and neck cancer (HNC) patient's compliance to the planned radiation therapy (RT) using the department policy established in 2005 at IPOCFG and to estimate the impact on treatment outcome due to failure in receiving RT as prescribed. MATERIALS AND METHODS: 359 HNC patients irradiated from 2007 to 2013 were included in this study. Patient cohort was divided into Group 1: patients receiving RT as prescribed and Group 2: patients that interrupted or suspended RT. Group Tox is the subgroup of patients that interrupted RT due to toxicity or intercurrent disease. Number and causes for treatment interruptions were assessed. The cumulative incidence of locoregional control (LRC), disease-free survival (DFS) and overall survival for Groups 1 and 2 was determined. Cox regression was performed to investigate potential hazard factors and logistic regression was made to determine risk factors related to treatment interruptions. RESULTS: Major causes for treatment interruptions were toxicity plus intercurrent disease (41.7 %) and public holidays (30.1 %). 10.3 % of the patients interrupted 3-9 days. Significant differences in survival distributions of the LRC between Groups 1 and 2, of up to 19 %, were found in the subgroup of patients with N2-3 tumours, for post-operative RT and for concomitant RT. Treatment breaks larger than two days had an almost fourfold increased risk of poorer LRC and DFS. CONCLUSIONS: Twin accelerators and treating on public holidays are effective measures minimizing RT breaks. For HNC, patient compliance is mostly limited by RT side-effects. Efforts to maintain RT biological effective dose in HNC must be always undertaken.
Peer review: yes
URI: http://hdl.handle.net/10773/16466
DOI: 10.1007/s12094-015-1417-5
ISSN: 1699-048X
Appears in Collections:CIDMA - Artigos

Files in This Item:
File Description SizeFormat 
2016 Ferreira OTT Clin Transl Oncol.pdf698.35 kBAdobe PDF    Request a copy


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.